Clinical trials: Stage II Skin Cancer
Breast Neoplasms
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.
This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor.
- Trial name
- NCT00034489
- Testing
- pemetrexed, gemcitabine
- Where
- United States
- Sponsor
- Eli Lilly and Company
Hand-Foot Skin Reaction (HFSR)
A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients.
- Trial name
- NOVA-II (NCT04088318)
- Testing
- OQL011, Vehicle Ointment
- Where
- 33 sites in United States, China and 1 more
- Volunteers
- 170 people
- Sponsor
- OnQuality Pharmaceuticals (USA) LLC
Thoracic Solid Malignant Tumor
Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA
To evaluate the safety and efficacy of Boron Neutron Capture Therapy (BNCT) in patients with recurrent thoracic solid tumors that are difficult to treat with standard radiation therapy or drug therapy and are unresectable.
- Trial name
- NCT06603987
- Testing
- BNCT, ［18F］FBPA
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Stella Pharma Corporation
Lymphedema
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection
This randomized phase III trial studies how well education with or without physical therapy intervention works in preventing lymphedema in women with stage I, II, or III breast cancer who are undergoing axillary lymph node…
- Trial name
- NCT00376597
- Testing
- quality of life assessment, educational intervention, Physical therapy
- Where
- 76 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Melanoma, Skin Cancer
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Background: Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor tissue. The cells are modified to help them kill tumor cells, then given back to the person with cancer.
- Trial name
- NCT01369875
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
- Trial name
- NCT06954831
- Testing
- Cone-Beam Computed Tomography, Hypofractionated External Beam Radiation Therapy, Questionnaire Administration
- Where
- 7 sites in United States
- Volunteers
- 82 people
- Sponsor
- City of Hope Medical Center
Metastatic Breast Cancer
A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to identify the highest tolerable dose of pyrotinib in combination with vinorelbine and to assess the safety and efficacy of the combination in Patients With HER2-Positive Locally Advanced or…
- Trial name
- NCT03997539
- Testing
- Pyrotinib, Treatment of physician's choice, vinorelbine
- Volunteers
- 256 people
- Sponsor
- Sun Yat-sen University
Breast Neoplasms
Study Assessing Efficacy of ZARNESTRA™ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the objective response rate when ZARNESTRA is added to treatment with tamoxifen
- Trial name
- NCT00210028
- Testing
- Tamoxifen, Zarnestra
- Where
- 3 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut Claudius Regaud
Melanoma (Skin)
Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma
RATIONALE: An infusion of a patient's lymphocytes that have been treated in the laboratory to remove certain immune cells may be an effective treatment for melanoma.
- Trial name
- NCT00138229
- Testing
- aldesleukin, filgrastim, therapeutic autologous lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
Urea Cream Treatment Sorafenib-Associated HSFR in HCC
Although sorafenib is effective and safe in patients with advanced hepatocellular carcinoma (HCC), it increases dermatologic toxicities, including hand-foot skin reaction (HFSR), which may have a negative impact on patient…
- Trial name
- NCT01934829
- Testing
- urea-based cream
- Where
- 11 sites in China
- Volunteers
- 871 people
- Sponsor
- Chinese Anti-Cancer Association
Breast Cancer, Endometrial Cancer
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
RATIONALE: Some hormones can stimulate the growth of some types of cancer cells. Hormone therapy using megestrol may fight cancer by reducing the production of these hormones.
- Conditions
- Breast Cancer, Endometrial Cancer, Malignant Mesothelioma
- Trial name
- NCT00002465
- Testing
- megestrol acetate
- Where
- United States
- Sponsor
- St. Vincent Medical Center - Los Angeles
Breast Cancer
ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial
The primary objective is to assess the event-free survival defined as the time from randomisation to progression, death without progression, loss to follow up, whichever occurred first..
- Trial name
- ZACFAST (NCT00752986)
- Testing
- ZD6474 (Vandetanib at the dose of 100 mg), Fulvestrant, ZD6474 (Vandetanib at the dose of 300 mg)
- Where
- 11 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Genzyme, a Sanofi Company
Melanoma
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
- Trial name
- NCT01673854
- Testing
- Ipilimumab, Vemurafenib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
Taxoprexin Treatment for Advanced Skin Melanoma
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population.
- Trial name
- NCT00249262
- Testing
- Taxoprexin
- Volunteers
- 30 people
- Sponsor
- American Regent, Inc.
Breast Cancer
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer.
- Trial name
- NCT00705315
- Testing
- Docetaxel, Epirubicin, Bevacizumab
- Where
- 10 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer
This study evaluates the addition melatonin and metformin to toremifene in the treatment of locally advanced breast cancer. Third of patients will receive toremifene, other third will receive combination of melatonin and…
- Trial name
- NCT02506790
- Testing
- metformin, Melatonin, Toremifene
- Where
- Russia
- Volunteers
- 96 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Breast Cancer, Vaginal Dryness
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with…
- Trial name
- NCT00343382
- Testing
- pilocarpine hydrochloride
- Where
- 192 sites in United States
- Volunteers
- 201 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Melanoma (Skin), Non-melanomatous Skin Cancer
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery
RATIONALE: The LMB-2 immunotoxin can find tumor cells and kill them without harming normal cells. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00295958
- Testing
- LMB-2 immunotoxin, MART-1 antigen, gp100 antigen
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
This is a Phase II, open-label, single arm study. The study will consist of an assessment of the safety and tolerability of tocilizumab administered concurrently at 4 mg/kg every 6 weeks for 5 doses in combination with ipilimumab…
- Trial name
- NCT03999749
- Testing
- Ipilimumab, Nivolumab, Tocilizumab
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- NYU Langone Health
Breast Cancer, Estrogen Receptor Negative Neoplasm
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.
- Conditions
- Breast Cancer, Estrogen Receptor Negative Neoplasm, HER-2 Positive Breast Cancer
- Trial name
- NCT02598310
- Testing
- nab-paclitaxel, Trastuzumab
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Osaka Medical College
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.